Moore John R (CIK 0001191702)

Latest company ownership

Role: General Counsel
Shares held
161,250
Last filed at
Aug 14, 2025
Confidence Score
49.1
2025Q4
Confidence Score History
2022Q2 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Aug 12, 2025 Aug 14, 2025 Edgewise Therapeutics, Inc. General Counsel Sell 46.3 -2,098 -17.04% $28.1K
May 1, 2025 May 7, 2025 Edgewise Therapeutics, Inc. General Counsel Sell 46.3 -1,930 -22.81% $31.8K
Sep 20, 2024 Sep 24, 2024 Edgewise Therapeutics, Inc. General Counsel Sell 17.5 -70,922 -91.60% $2M
May 1, 2024 May 3, 2024 Edgewise Therapeutics, Inc. General Counsel Sell 46.3 -1,956 -37.56% $37K
Feb 7, 2024 Feb 9, 2024 Edgewise Therapeutics, Inc. General Counsel Sell 7.5 -29,835 -100.00% $596.8K
Dec 27, 2023 Dec 28, 2023 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -8,497 -100.00% $89.2K
May 1, 2023 May 3, 2023 Edgewise Therapeutics, Inc. General Counsel Sell 46.3 -1,897 -22.42% $16.9K
Oct 3, 2022 Oct 5, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 13.8 -4,730 -61.19% $46.2K
Sep 6, 2022 Sep 8, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -4,730 -61.19% $51.6K
Aug 3, 2022 Aug 5, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -9,232 -75.47% $85.9K
Jul 5, 2022 Jul 7, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -9,232 -60.61% $77.3K
Jun 16, 2022 Jun 21, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 7.5 -67,927 -88.30% $463.9K
Jun 13, 2022 Jun 15, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -26,381 -46.73% $160.5K
Jun 8, 2022 Jun 10, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -27,306 -75.21% $175.9K
Jun 3, 2022 Jun 7, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 7.5 -47,287 -79.76% $296K
May 16, 2022 May 18, 2022 Edgewise Therapeutics, Inc. General Counsel Sell 10.0 -10,800 -78.26% $80.1K